Capital Advisors Inc Crispr Therapeutics Ag Transaction History

Capital Advisors Inc

  • $4.88 Billion
  • Q4 2024

A detailed history of Capital Advisors Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Capital Advisors Inc holds 310,270 shares of CRSP stock, worth $13.6 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
310,270
Previous 300,589 3.22%
Holding current value
$13.6 Million
Previous $14.1 Million 13.54%
% of portfolio
0.25%
Previous 0.29%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 29, 2025
BUY
$38.65 - $55.15 $374,170 - $533,907
9,681 Added 3.22%
310,270 $12.2 Million
Q3 2024

Oct 28, 2024
BUY
$44.62 - $62.75 $1.01 Million - $1.42 Million
22,583 Added 8.12%
300,589 $14.1 Million
Q2 2024

Jul 31, 2024
BUY
$51.17 - $68.18 $717,403 - $955,883
14,020 Added 5.31%
278,006 $15 Million
Q1 2024

Apr 29, 2024
BUY
$60.67 - $89.12 $529,103 - $777,215
8,721 Added 3.42%
263,986 $18 Million
Q4 2023

Jan 29, 2024
BUY
$38.62 - $72.18 $901,390 - $1.68 Million
23,340 Added 10.06%
255,265 $16 Million
Q3 2023

Oct 24, 2023
BUY
$45.39 - $59.0 $724,015 - $941,109
15,951 Added 7.39%
231,925 $10.5 Million
Q2 2023

Jul 18, 2023
BUY
$43.47 - $67.77 $2.18 Million - $3.4 Million
50,193 Added 30.28%
215,974 $12.1 Million
Q1 2023

Apr 19, 2023
BUY
$41.0 - $56.12 $1.47 Million - $2.01 Million
35,867 Added 27.61%
165,781 $7.5 Million
Q4 2022

Jan 17, 2023
BUY
$39.19 - $65.67 $60,822 - $101,919
1,552 Added 1.21%
129,914 $0
Q3 2022

Oct 17, 2022
BUY
$61.1 - $83.78 $151,344 - $207,523
2,477 Added 1.97%
128,362 $8.39 Million
Q2 2022

Jul 15, 2022
BUY
$43.23 - $73.83 $903,636 - $1.54 Million
20,903 Added 19.91%
125,885 $7.65 Million
Q1 2022

May 05, 2022
BUY
$53.19 - $79.24 $133,506 - $198,892
2,510 Added 2.45%
104,982 $6.59 Million
Q4 2021

Jan 27, 2022
BUY
$70.09 - $111.29 $2.23 Million - $3.54 Million
31,800 Added 45.0%
102,472 $7.77 Million
Q3 2021

Oct 25, 2021
BUY
$110.2 - $156.64 $131,248 - $186,558
1,191 Added 1.71%
70,672 $7.91 Million
Q2 2021

Aug 02, 2021
BUY
$100.84 - $161.89 $173,848 - $279,098
1,724 Added 2.54%
69,481 $11.2 Million
Q1 2021

May 25, 2021
SELL
$110.72 - $210.04 $2.2 Million - $4.18 Million
-19,911 Reduced 22.71%
67,757 $8.26 Million
Q4 2020

Feb 08, 2021
SELL
$79.67 - $173.23 $3.92 Million - $8.53 Million
-49,232 Reduced 35.96%
87,668 $13.4 Million
Q3 2020

Nov 02, 2020
BUY
$78.5 - $100.64 $31,635 - $40,557
403 Added 0.3%
136,900 $11.5 Million
Q2 2020

Aug 07, 2020
BUY
$38.5 - $76.05 $112,343 - $221,913
2,918 Added 2.18%
136,497 $12.7 Million
Q1 2020

May 21, 2020
BUY
$33.68 - $62.53 $220,604 - $409,571
6,550 Added 5.16%
133,579 $5.67 Million
Q4 2019

Feb 04, 2020
BUY
$36.68 - $73.13 $398,784 - $795,069
10,872 Added 9.36%
127,029 $7.74 Million
Q2 2019

Aug 07, 2019
BUY
$35.45 - $48.2 $2.26 Million - $3.07 Million
63,678 Added 121.34%
116,157 $0
Q1 2019

May 10, 2019
SELL
$28.02 - $40.87 $1.83 Million - $2.67 Million
-65,340 Reduced 55.46%
52,479 $0
Q4 2018

Feb 06, 2019
BUY
$22.73 - $42.34 $236,096 - $439,785
10,387 Added 9.67%
117,819 $3.37 Million
Q3 2018

Nov 13, 2018
BUY
$44.35 - $65.71 $43,950 - $65,118
991 Added 0.93%
107,432 $4.77 Million
Q2 2018

Aug 06, 2018
SELL
$42.62 - $73.59 $1.81 Million - $3.13 Million
-42,476 Reduced 28.52%
106,441 $0
Q1 2018

May 04, 2018
SELL
$23.52 - $58.17 $18,510 - $45,779
-787 Reduced 0.53%
148,917 $0
Q4 2017

Jan 29, 2018
BUY
$16.95 - $23.48 $2.54 Million - $3.52 Million
149,704
149,704 $3.52 Million

Others Institutions Holding CRSP

# of Institutions
487
Shares Held
64.1M
Call Options Held
1.64M
Put Options Held
1.93M
View Full List

About CRISPR Therapeutics AG

CRSP Quotes by TradingView
  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.42B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Capital Advisors Inc Portfolio

Follow Capital Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Capital Advisors Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email